Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a cluster of bone marrow disorders in which blood cell production goes awry. The marrow makes abnormal cells that either die prematurely or fail to function properly, leaving the body short of healthy red cells, white cells, or platelets. MDS is more common after age 60 and can range from a slowly progressing condition managed with supportive care to a more aggressive form that may transform into acute leukaemia.

Medicine used to treat Myelodysplastic Syndromes

What goes wrong in MDS

Healthy bone marrow continuously replaces worn-out blood cells. In MDS, genetic mutations inside stem cells disrupt this process. The faulty cells crowd the marrow without maturing correctly, producing a build-up of immature blasts. The result is anaemia (fatigue, breathlessness), an increased infection risk from low white cell counts, and easy bruising or bleeding when platelet numbers fall. Symptoms can be subtle for years before a routine blood test reveals abnormal counts.

How MDS is treated

Treatment depends on the risk category assigned at diagnosis. Low-risk cases may be managed with growth factors or transfusions alone. Higher-risk MDS often calls for disease-modifying therapy; lenalidomide is used in specific subtypes, particularly those with a chromosome 5q deletion, where it can reduce transfusion dependence meaningfully. For eligible patients, stem cell transplant remains the only potentially curative option. Broader context on haematological treatments is covered under oncology support.

Unexplained persistent fatigue, recurrent infections, or unusual bruising warrants prompt investigation rather than watchful waiting.